Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) Operating Expenses (2017 - 2025)

Historic Operating Expenses for Dianthus Therapeutics (DNTH) over the last 8 years, with Q3 2025 value amounting to $40.7 million.

  • Dianthus Therapeutics' Operating Expenses rose 2685.21% to $40.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $143.4 million, marking a year-over-year increase of 6244.02%. This contributed to the annual value of $108.1 million for FY2024, which is 11195.88% up from last year.
  • According to the latest figures from Q3 2025, Dianthus Therapeutics' Operating Expenses is $40.7 million, which was up 2685.21% from $35.1 million recorded in Q2 2025.
  • Over the past 5 years, Dianthus Therapeutics' Operating Expenses peaked at $40.7 million during Q3 2025, and registered a low of $8.2 million during Q1 2023.
  • For the 4-year period, Dianthus Therapeutics' Operating Expenses averaged around $22.3 million, with its median value being $18.7 million (2024).
  • Its Operating Expenses has fluctuated over the past 5 years, first surged by 1301.82% in 2023, then skyrocketed by 14783.42% in 2024.
  • Over the past 4 years, Dianthus Therapeutics' Operating Expenses (Quarter) stood at $11.9 million in 2022, then grew by 13.02% to $13.4 million in 2023, then surged by 147.83% to $33.2 million in 2024, then increased by 22.39% to $40.7 million in 2025.
  • Its last three reported values are $40.7 million in Q3 2025, $35.1 million for Q2 2025, and $34.3 million during Q1 2025.